This is a contract result notice, not an open opportunity. Details from the official award data.

The procurement contact named on the official notice.

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 Offer reference number: CM/PHS/25/5728 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Potential periods of call-offs under the framework agreement: CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National) 01/12/2025 to 31/05/2027 (18 months) CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg: NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months) LNW: (London) 01/12/2025 to 31/05/2027 (18 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England.

To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye